| Document |
Document Title |
|
WO/2018/228205A1 |
Disclosed are a 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carbox
amide hydrochloride polymorph, a preparation method therefor and an application thereof. Specifically, disclosed are three crystalline forms, i.e., crystalline ...
|
|
WO/2018/231015A1 |
The present specification relates to an anthracene derivative represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2018/232298A1 |
The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus
|
|
WO/2018/216030A9 |
The present invention discloses a single step process for the synthesis of furan derivative from carbohydrate comprises stirring the reaction mixture of carbohydrate in solvent in presence of catalyst at temperature in the range of 170 t...
|
|
WO/2018/231013A1 |
The present specification relates to an anthracene derivative represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2018/223970A1 |
The present invention relates to a new preparation method for escitalopram pamoate ((S)-(+)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-
dihydro-5 cyanoisobenzofuran pamoate), wherein the method is environmentally friendly and pol...
|
|
WO/2018/225520A1 |
Provided are: a compound represented by general formula (i); and a composition and a liquid crystal display element which use said compound. The compound represented by general formula (i) is obtained by reacting a compound represented b...
|
|
WO/2018/226102A1 |
The present invention is directed to methods for the preparation of eremophila-1(10)-11(13)-dien-12,8β-olide (EPD) and analogues thereof.
|
|
WO/2018/225018A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2018/225549A1 |
Provided is a fluorine-containing polymer which does not contain a perfluoroalkyl group having 4 or more carbon atoms, and which serves as a pattern forming material that enables the achievement of a pattern having high sensitivity and h...
|
|
WO/2018/004096A9 |
The present invention relates to a compound, for an organic optoelectronic device, expressed by chemical formula (1), a composition for an organic optoelectronic device, an organic optoelectronic device having applied same, and a display...
|
|
WO/2018/218281A1 |
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.
|
|
WO/2018/220003A1 |
The present invention relates to a process for the hydrogenation of a composition comprising hydroxymethylfurfural, bishydroxymethylfuran or mixtures thereof to obtain a composition comprising cis-(tetrahydrofuran-2,5-diyl)dimethanoland ...
|
|
WO/2018/220634A1 |
The invention generally provides a method for the synthesis of a π-conjugated system from oligofurans, under conditions involving cycloaddition.
|
|
WO/2018/222444A1 |
Embodiments of the disclosure relate to methods of selectively depositing organic and hybrid organic/inorganic layers. More particularly, embodiments of the disclosure are directed to methods of modifying hydroxyl terminated surfaces for...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/214961A1 |
The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceuti...
|
|
WO/2018/214676A1 |
The present invention provides a method suitable for mass-producing a buagafuran active pharmaceutical ingredient. A buagafuran active pharmaceutical ingredient with high purity can be prepared by the method and can be applied to a new d...
|
|
WO/2018/217894A1 |
The invention relates to halichondrin derivatives containing fluorine, e.g., fluorine-18, as well as methods of synthesizing the same.
|
|
WO/2018/209616A1 |
Provided are an α-amino acrylate microbicide, and a preparation method therefor and uses thereof. Based on the principle of pesticide molecular design, the structural reform of the agricultural anti-plant virus activity is carried on le...
|
|
WO/2018/209973A1 |
The present invention provides compounds as represented by structural formula (I), its S-isomers and R-isomers, and its pharmaceutically acceptable salts. In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 ar...
|
|
WO/2018/213236A1 |
The present invention relates to the unexpected discovery of novel multi-aromatic, multi-substituted compounds. In certain embodiments, the compounds of the invention are generated by condensing at least two phenolic- and/or aniline-cont...
|
|
WO/2018/211516A1 |
The present application relates to derivatives of tricyclic spirolactones compounds of formula (I) and compositions thereof and uses thereof in treatment and management of pain. Formula (I).
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/209972A1 |
The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of...
|
|
WO/2018/210297A1 |
Disclosed are an intermediate of Eribulin and a preparation method therefor. In particular, disclosed are compounds as represented by formula II, formula III and formula V and a preparation method therefor. Ar is C1-10 alkyl substituted,...
|
|
WO/2018/213442A1 |
A diastereoselective method of preparing benzofuran-based 4,5-spirocycles via metal catalyzed alkenylation is described. The method can be used to provide compounds containing the benzofuranone-4,5-spirocyclic motif of the phainanoids, a...
|
|
WO/2018/209665A1 |
A preparation method for a nano-nickel-based catalyst with a confinement structure and hexahedral morphology. According to the method, a nickel-aluminum hydrotalcite precursor of an organic carbon chain intercalation is synthesized first...
|
|
WO/2018/207888A1 |
The present invention provides a method for simply and efficiently producing ramelteon, which is a sleep-inducing agent. According to the present invention, ramelteon can be produced through a few steps including a step in which (E)-2-[1...
|
|
WO/2018/207812A1 |
The purpose of the present invention is to provide therapeutic agents for bedsore and skin wound and methods for treating bedsore and skin wound. The present invention provides a bedsore therapeutic agent or a bedsore treatment method or...
|
|
WO/2018/208712A1 |
The present application discloses stilbene derivative compounds and phenyl- benzofuran compositions, useful in the manufacture of dye-sensitized solar cells and other similar technology.
|
|
WO/2018/203171A1 |
An organic compound has a benzonaphthofuran skeleton and is represented by Formula (G1). In Formula (G1), A represents a pyrene skeleton. In the case where the pyrene skeleton has a substituent, the substituent is a diarylamino group inc...
|
|
WO/2018/202681A1 |
The invention is in the technical field of insect control and relates to the use of a disubstituted benzenes for controlling insecticide-resistant pests such as mosquitoes and cockroaches.
|
|
WO/2018/203564A1 |
Provided is an inhibitor of at least one type of kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2､TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the inhibitor containing, as an active...
|
|
WO/2018/202525A1 |
The invention is in the technical field of insect control and relates to novel phenoxyethanamine derivatives, their production and use for controlling pests and in particular insecticide-resistant pests such as mosquitoes and cockroaches.
|
|
WO/2018/198975A1 |
Provided is a light-emitting element having excellent luminance life. Disclosed is a light-emitting element comprising a positive electrode, a negative electrode, a first organic layer provided between the positive electrode and the nega...
|
|
WO/2018/199466A1 |
The present invention provides a novel compound and an organic light-emitting element including same.
|
|
WO/2018/198974A1 |
Provided is a light-emitting element having excellent luminance life. This light-emitting element comprises: a positive electrode; a negative electrode; and a first organic layer and a second organic layer provided between the positive e...
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/189683A1 |
The present invention refers to benzofuran derivatives, capable of efficaciously activating the enzymatic complex AMPK, useful for the prophylaxis and therapeutic treatment of diseases and disorders in particular metabolic disorders such...
|
|
WO/2018/190682A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using the same.
|
|
WO/2018/189060A1 |
The invention comprises novel chiral metal complex compounds of the formula (I) wherein M, PR2, R3 and R4 are outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter io...
|
|
WO/2018/190294A1 |
The present invention mainly addresses the problem of providing a novel medicinal composition which comprises escitalopram as an active ingredient and has secured stability (light stability and heat stability) as a medicine. The present ...
|
|
WO/2018/190516A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting element utilizing same.
|
|
WO/2018/188763A1 |
The present invention concerns a process for the preparation of firocoxib, i.e. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylpheny
l)-furan-2-one, comprising steps (a)-(g), wherein the process provides for step (d) of the react...
|
|
WO/2018/188795A1 |
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.
|
|
WO/2018/183523A1 |
An enhanced pyrotechnic composition including an obscurant, a fuel, an oxidizer, and a nonivamide-cyclic anhydride adduct.
|
|
WO/2018/178304A1 |
Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.
|
|
WO/2018/176803A1 |
A hydrophobic palladium/metal organic frame material, which is a solid catalyst material obtained by using a porous metal organic frame as a carrier, introducing elemental palladium by means of an imersion-reduction method, and then perf...
|
|
WO/2018/176133A1 |
The present invention relates to the preparation of compounds of Formula I, including thapsigargin, nortrilobolide and 8-O-debutanoyl-thapsigargin from commercially available (R)-(-)-carvone via synthetic intermediate compound of formula...
|
